ClinicalTrials.gg
CompletedNCT06727396Updated Feb 27, 2026

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

A Phase 1 interventional study of CKD-508 Tablet and Placebo Tablet in Healthy Subjects, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This Phase 1, randomized, parallel-group, placebo-controlled, double-blinded study aims to evaluate the safety, PK, and PD of CKD-508 when administered multiple times once daily to healthy participants.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is capable of providing signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the protocol.
  • Male and female adults aged 18 to 55 years at screening.
  • Healthy participants were determined by pre-study medical evaluation and judged by the Investigator.
  • Female participants of non- (surgically sterile [hysterectomy or oophorectomy]) or (amenorrhea for more than 12 months with follicle-stimulating hormone [FSH] in the postmenopausal range as confirmed by an FSH test).
  • Female participants of childbearing potential who agree to use highly effective method of in the protocol consistently and correctly from screening until the last dose administration of the study intervention.
  • Male participants must be unable to procreate (defined as surgically sterile [had a vasectomy] ≥6 months prior screening) or must agree to use a highly effective contraception as detailed in the protocol during the intervention period and for at least 90 days after the study completion and refrain from donating sperm during this period.
  • Non-smoker (or other nicotine use) as determined by history (no nicotine use over the past 6 months) and by urine cotinine concentration (\<200 ng/mL) at screening and admission.

Exclusion criteria

Exclusion Criteria:

  • History or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder as determined by the Investigator.
  • Presence of any disorder that would interfere with the absorption, distribution, metabolism, or excretion of study intervention as judged by the Investigator.
  • Serum alkaline phosphatase (ALP) or total ≥ (ULN), or (ALT) or aspartate aminotransferase (AST) >ULN at either screening or admission.
  • Abnormal renal function with estimated (eGFR) \<90 mL/min/1.73 m2 at screening.
  • History or presence of clinically significant abnormal cardiac automaticity, heart rhythm, findings, or other relevant conditions that may pose a risk to the participants as judged by the Investigator.
  • History of alcohol and/or illicit drug abuse within 2 years before screening or positive urine test for alcohol or positive urine drug test at screening or admission.
  • Positive test for , , or antibody at screening.
  • Currently taking a lipid-modifying medication.
  • History of to CKD-508 or medicinal products with similar chemical structures.
  • Individual unlikely to comply with the protocol requirements, instructions, and study-related restrictions.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    CKD-508 dose level 1

    Multiple dose of CKD-508 tablets

    Drug: CKD-508 Tablet

  • Experimental
    CKD-508 dose level 2

    Multiple dose of CKD-508 tablets

    Drug: CKD-508 Tablet

  • Experimental
    CKD-508 dose level 3

    Multiple dose of CKD-508 tablets

    Drug: CKD-508 Tablet

  • Experimental
    CKD-508 dose level 4

    Multiple dose of CKD-508 tablets

    Drug: CKD-508 Tablet

  • Placebo comparator
    Placebo

    Multiple dose of placebo tablets

    Drug: Placebo Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience a Treatment-Emergent Adverse Event (TEAE)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE will be defined as any AE that emerges during treatment (i.e., AE which starts during or after study drug administration or pre-existed and worsened in severity after study drug administration), and those will be analyzed for the purpose of safety analysis. The number of participants who experience a TEAE will be reported.

    Time frame: up to Day 56

  2. Maximum Plasma Concentrations of CKD-508 after single and multiple doses

    Peak plasma concentration (Cmax)

    Time frame: up to Day 56

  3. Time to Maximum Plasma Concentrations of CKD-508 after single and multiple doses

    Time of peak plasma concentration (Tmax)

    Time frame: up to Day 56

  4. Area Under the Concentration-Time Curve of CKD-508 after single dose

    Area under the concentration-time curve from pre-dose (time 0) to post-dose 24 h (AUC0-24h) after a single dose

    Time frame: up to 24 hours post-dose

  5. Area Under the Concentration-Time Curve of CKD-508 after multiple doses

    Area under the concentration-time curve from pre-dose (time 0) to post-dose 24 h (AUCtau.ss) after multiple doses

    Time frame: up to Day 56

  6. Change from baseline in CETP activity after multiple doses of CKD-508 or placebo

    The absolute values and percentages of change from baseline in CETP activity measured in blood after multiple doses of CKD-508 or placebo

    Time frame: up to Day 56

Secondary outcomes

  1. Change from Baseline in Low-density Lipoprotein Cholesterol (LDL-C) after multiple doses of CKD-508 or placebo

    The absolute values and percentages of change from baseline in LDL-C measured in blood after multiple doses of CKD-508 or placebo

    Time frame: up to Day 40

  2. Change from Baseline in High-density Lipoprotein Cholesterol (HDL-C) after multiple doses of CKD-508 or placebo

    The absolute values and percentages of change from baseline in HDL-C measured in blood after multiple doses of CKD-508 or placebo

    Time frame: up to Day 40

  3. Change from Baseline in CETP mass after multiple doses of CKD-508 or placebo

    The absolute values and percentages of change from baseline in CETP protein concentration measured in blood after multiple doses of CKD-508 or placebo

    Time frame: up to Day 56

  4. The effects on the cardiac repolarization by assessing the QTc interval after single and multiple doses of CKD-508 or placebo

    Time frame: up to Day 56

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Jun 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 10, 2024
StartActual
Nov 14, 2024
Primary completionActual
Jun 5, 2025
CompletionActual
Jun 5, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06727396
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Nov 14, 2024
Primary completion
Jun 5, 2025
Completion
Jun 5, 2025
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CKD-508

Start the discussion